Olr657 inhibitors represent a unique and specialized class of chemical compounds that primarily interact with the Olr657 receptor, a member of the olfactory receptor family. These receptors are a subgroup within the larger G protein-coupled receptor (GPCR) family, known for their role in the detection of odor molecules. Olr657, specifically, is involved in the binding and response to particular odorants, playing a crucial part in the complex signaling pathways that facilitate the sense of smell. Inhibitors of Olr657 are designed to interfere with the receptor's normal function, providing a means to study the intricate mechanisms of olfactory signaling. These inhibitors can bind to the receptor, preventing the activation by its natural ligands, thereby allowing researchers to dissect the receptor's role in various olfactory processes and its contribution to the broader olfactory system.
The development and study of Olr657 inhibitors also provide valuable insights into the structural and functional aspects of GPCRs. By analyzing how these inhibitors interact with Olr657, scientists can infer details about the receptor's binding sites, conformational changes upon ligand binding, and subsequent intracellular signaling cascades. This knowledge extends beyond olfaction, contributing to a deeper understanding of GPCR functionality in general. Furthermore, the specificity and potency of Olr657 inhibitors are of particular interest, as they highlight the nuanced interplay between receptor structure and ligand design. Advanced techniques in molecular modeling, computational chemistry, and structural biology are often employed to refine these inhibitors, enhancing their selectivity and efficacy. Thus, Olr657 inhibitors are not only pivotal in olfactory research but also serve as a model for studying GPCR interactions and inhibition strategies in a broader scientific context.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Non-selective beta-adrenergic antagonist, might modulate GPCR activity affecting Olr657. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr657. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, potentially influencing Olr657 signaling. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, might indirectly affect GPCR pathways including Olr657. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, could influence GPCR-mediated signaling pathways related to Olr657. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Non-selective beta-adrenergic agonist, could indirectly affect Olr657 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, might influence GPCR signaling pathways including Olr657. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Long-acting beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr657. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Non-selective beta blocker, could indirectly influence GPCR signaling pathways including Olr657. | ||||||